21 February 2013
ASX RELEASE
Novogen demerger– tax implications
The demerger of Novogen and MEI Pharma is now complete. IRS Form 8937,
together with a report for all shareholders on the tax implications of the
demerger, are now available on the Novogen website www.novogen.com/
About Novogen
Novogen Ltd is a public Australian biotechnology company whose shares trade
on both the Australian Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol
‘NVGN’). The Company is based in Sydney, Australia and is focused on the
development of a family of novel anti-cancer drugs based on super-benzopyran
and ‘stealth’ drug technologies. The Company’s inaugural drug candidate is CS-6.
About CS-6
CS-6 belongs to a new class of drug candidates intended to treat most forms of
cancer in a comprehensive manner, targeting both cancer cells and their
progenitors, the cancer stem cells. CS-6 shows broad anti-proliferative and
cytotoxic activity against human cancer cells, with particular activity against
human glioblastoma cells. CS-6 also has been designed deliberately to meet the
major known criteria for crossing the blood-brain barrier, and for that reason is
being developed as a first-line for the treatment of glioblastoma multiforme, the
main form of primary brain cancer.
Further information
Contact Dr Graham Kelly, Chief Executive Officer.
T: (61 2) 9878 0088
M: (61) 0459 200 095
E: Graham.Kelly@novogen.com
Further information is available on the Company’s web site, www.novogen.com